Targeting Upstream Neurodegeneration: LM11A-31 in Alzheimer Disease and PSP

Therapeutic development in Alzheimer disease has increasingly shifted toward strategies that extend beyond targeting single pathological hallmarks such as amyloid or tau. Emerging approaches are now focused on upstream regulators that influence multiple downstream neurodegenerative processes, with the goal of achieving broader disease modification and improving neuronal resilience.

LM11A-31, an investigational oral agent developed by PharmatrophiX, represents one such approach. The therapy targets the p75 neurotrophin receptor, a key regulator of neuronal survival and synaptic integrity, with the potential to modulate interconnected pathways involving tau pathology, amyloid-related signaling, and neuroinflammation. In a phase 2a study of patients with mild-to-moderate Alzheimer disease, LM11A-31 demonstrated favorable safety and early biomarker signals suggestive of disease-modifying effects, alongside trends toward slowed cognitive decline.

More recently, the therapy has been selected for inclusion in a University of California, San Francisco and Cure PSP-led platform trial in progressive supranuclear palsy (PSP), reflecting growing interest in its applicability across tauopathies. In a Q&A with NeurologyLive^®, David Setboun, PharmD, MBA, and Frank Longo, MD, PhD, discussed the mechanistic rationale of LM11A-31, early clinical findings, and the evolving role of platform trials in advancing neurodegenerative therapeutics.

NeurologyLive: Can you briefly summarize the mechanism of action of LM11A-31 and how targeting upstream regulators may influence downstream neurodegenerative processes?

David Setboun, PharmD; Frank Longo, MD, PhD: LM11A-31 targets the p75 neurotrophin receptor, which is expressed by neurons where it regulates their overall health. During brain development, p75 regulates which neurons and synapses are eliminated, thus one of its core functions is regulation of fundamental signaling networks within the neuron that maintain its integrity and survival.

We have discovered that the signaling network regulated by p75 has remarkable overlap with the degenerative signaling networks activated by amyloid and pathological forms of tau and that are active in Alzheimer’s disease. LM11A-31 modulates p75 function to downregulate these degenerative signaling networks and upregulated signaling related to synaptic resilience.

Another key effect of LM11A-31 on p75 is to downregulate signaling mechanisms upstream of tau that led to the accumulation of pathological forms of tau.

Overall, we have identified eight different tauopathy pathological mechanisms that are inhibited by LM11A-31. In AD and other pathological states, p75 is also upregulated in microglial, the brain’s inflammatory cells, and LM11A-31 can downregulate disease-associated states and degenerative activities of microglial. A key concept is that regulation of the p75 receptor addresses fundamental biological mechanisms related to all three areas of amyloid, tau and inflammatory processes, that results in synaptic resilience and that are not limited to single pathological features of AD.

What were the key safety and biomarker findings from the phase 2a study, and how should clinicians interpret these early signals in the context of Alzheimer disease?

In a phase 2a study that assessed 242 patients with mild-to-moderate Alzheimer’s disease, LM11A-31 showed benefits across five biomarker categories that each correlate with cognitive function, slowed cognitive decline by ~50% vs. placebo on both cognition scale measures ADAS-cog13 & MMSE, and demonstrated a favorable safety profile with mild, transient adverse events and no treatment-related amyloid-related imaging abnormalities.

Clinicians should view these findings as not only early evidence of disease modification but also with optimism for the future of neuroprotective therapies and those that target multiple intracellular tau mechanisms.

As a Phase 2a study, this trial in a mild to moderate population was a relatively short (26-weeks). The trial shows statistically significant results in 5 distinct categories of biomarkers, each biomarker correlating with cognition. While not powered for a formal cognitive assessment, the hypothesis is consistent with the direction of slowing of cognitive decline along with the consistency of the biomarker data across the five categories are promising results to prepare for future larger studies.

LM11A-31 has been selected for a platform trial in progressive supranuclear palsy. What is the rationale for evaluating this agent across multiple neurodegenerative conditions?

Progressive Supranuclear Palsy (PSP) is a primary tauopathy and LM11A-31 targets at least eight fundamental tau pathological mechanisms that are directly relevant to PSP and other tauopathies. These include inhibition of multiple post-translational modifications of phosphorylation and acetylation; tau misfolding, mislocalization within neurons, tau cleavage, tau oligomerization, tau seeding, accumulation of paired helical filaments and tau spreading.

Each of these pathological events individually have been considered as potentially important therapeutic targets, thus we are encouraged to have a single ‘upstream’ therapy that engages all eight mechanisms. In addition, a recent perspective is that it will be critical to target intracellular tau pathology which modulation of p75 achieves.

From a clinical development perspective, what are the advantages of a platform trial design in rare neurodegenerative diseases like PSP?

Platform trial designs offer several key advantages in rare neurodegenerative diseases like PSP, where patient populations are limited and efficient study execution is critical. They allow multiple therapies to be evaluated simultaneously under a shared infrastructure, reducing the need for separate trials and minimizing patient recruitment challenges. A common control arm further improves efficiency and reduces costs by decreasing the number of participants required to receive placebo. These designs are also adaptive, enabling ineffective treatments to be dropped and promising ones to be added over time, which accelerates decision-making.

Looking ahead, what key endpoints or outcomes will be most important in determining whether LM11A-31 can meaningfully impact disease progression?

Key endpoints will focus on demonstrating a consistent impact on disease progression across biomarkers and clinical measures including cognitive and functional status.

Biomarkers relevant to p75 function and those related go clinical status will continue to be important in providing early evidence of disease modification, including, structural MRI as a measure of degradation, FDG-PET as a marker of synaptic function, and fluid markers within cerebral spinal fluid and blood of synaptic integrity, neuroinflammation, and tau pathology.

Ultimately, alignment between biomarker improvements and sustained clinical benefit over longer treatment durations will be key to establishing a meaningful impact on disease progression.